Dendritic cells (DCs) are a rare type of immune cells that scan the body for infectious invaders and cancers. Once identified, DCs train the immune system to destroy these attackers; keeping us healthy. Because of these skills, DCs are currently in the focus of anti-cancer vaccine research.The messenger molecule type I IFN, which is produced in large quantities by the specialized plasmacytoid DCs, plays a central role in the initiation of immune responses. Understanding how pDCs control the production of type I IFN is key to more effective treatment, but our knowledge of the cellular mechanisms is incomplete.
Researchers from Radboudumc and Eindhoven University of Technology developed a high-throughput nano lab to shed light on this process. Last week, their findings were published in Nature Communications.
Using their device, the researchers around Florian Wimmers (Radboudumc, Stanford University) tested thousands of single pDCs for their ability to produce type I IFN. Remarkably, they discovered that only a tiny subset of single pDCs produces type I IFN. When these cells were mixed with other pDCs, crosstalk between individual cells within the population led to a boost in activity. The results of the team around Wimmers that was supervised by Jurjen Tel (TUE) and Jolanda de Vries (Radboudumc) will help to design better cancer treatments. Interventions that target pDCs inside the body should consider that not all pDCs are the same and that the local density of pDCs is an important indicator of their activity.The nano lab that the team used for this analysis was developed in collaboration with Wilhelm Huck (Radboud University) and Carl Figdor (Radboudumc). The device generates millions of tiny droplets, each containing a single cell. Researchers study the behavior of the captured cells at high-throughput to better understand cell-cell variability and the fundamental rules of cellular communication.
Related news items
How do we keep new technology affordable to improve the lives of people?16 May 2019
Improving healthcare by means of new technological developments? We need to change the entire approach for evaluating the true impact , says Maroeska Rovers. By bringing together all stakeholders from the beginning, millions of euros can be saved.read more
Dutch Kidney Foundation Innovation grant for Tom Nijenhuis14 May 2019
Tom Nijenhuis, theme Renal disorders, received this grant for his research project “Salt supplementation in Gitelman syndrome: A simple intervention using an innovative N-of-1 trial approach”.read more
Algorithm calculates the presence and aggressiveness of prostate tumors14 May 2019
A computer program that analyzes MRI images can reliably map the presence and even the aggressiveness of a prostate tumor. This is what Radboudumc researchers and international colleagues have published in the scientific journal Investigative Radiology.read more
Universal tumor BRCA1/2 testing of ovarian cancer13 May 2019
Marjolijn Ligtenberg, Janet Vos and Nicoline Hoogerbrugge, assessed the feasibility of a workflow for universal tumor DNA BRCA1/2 testing of all newly diagnosed OC patients as prescreen for PARPi treatment and cancer predisposition testing. They have published their findings in the JNCI.read more